To the Editor:
Fish is a healthy nutrient and a common food allergen. Crossreactivity between fish species exists, and some patients report tolerance to certain species 1 but data from food-challenge trials are scarce. 2, 3 Parvalbumin is the major fish allergen [4] [5] [6] while recently fish muscle enolases and aldolases were identified as new fish allergens. 7 We present the first double-blind, placebocontrolled food-challenge (DBPCFC) trial with different fish species, evaluating the correlation between clinical reactivity and IgE reactivity to fish-allergen molecules in fish-allergic patients.
In this trial, 35 subjects (5-19 years) with physician-diagnosed fish allergy and sensitization to fish allergen underwent DBPCFC with cod, salmon, and mackerel, followed by open food challenges (OFCs) if DBPCFCs were negative. Study design (Fig E1) , patients' background characteristics (Table E1 ), and methods are described in this article's Online Repository at www.jacionline.org.
Any allergic symptoms were observed/reported from 33 (cod), 28 (salmon), and 28 (mackerel) participants. Five participants reported mild, transient subjective symptoms on placebo challenge but had unequivocal findings during the DBPCFC-active arm and are thus included in the analysis (see Table E2 in this article's Online Repository at www.jacionline.org).
We found tolerance to at least 1 of 3 fish species (partially tolerant) in 10 (29%) participants regarding any symptoms (Table I) . Table II presents reactivity in partially tolerant participants. There was no difference between nontolerant (reacting to all 3 fish species) and partially tolerant participants regarding age, sex, other allergies, parental allergy, asthma, or atopic dermatitis.
Oral itching and swellings/blisters were the most frequent subjective and objective symptoms, respectively (see Fig E2, A and B, in this article's Online Repository at www.jacionline. org). Involvement of more than 1 organ was seen in 14 of 35 participants. Upon challenge, 2 participants received adrenaline, but none had severe anaphylaxis requiring further observation or treatment.
Sensitization to all 3 fish-allergen extracts and parvalbumins was found in nearly all participants, whereas sensitization to enolases/aldolases was predominantly found in participants with objective symptoms (Fig 1, A-C) . However, many participants with objective symptoms were not sensitized to the corresponding enolase/aldolase.
Nontolerant participants had higher sIgE levels to fish-allergen extracts and parvalbumins compared with partially tolerant participants, whereas no difference was seen for enolase and aldolase (see Table E3 in this article's Online Repository at www. jacionline.org). Specific IgE to extracts from cod and salmon discriminated best between nontolerant and partially tolerant groups. IgE level of more than 8.2 kU A /L to cod extract or more than 5.0 kU A /L to salmon extract identified 18 of 24 and 19 of 24 nontolerant participants, respectively, whereas below these cutoff values, 8 of 10 and 9 of 10 partially tolerant participants were identified (see Fig E3 in this article's Online Repository at www.jacionline.org).
Finally, we estimated the eliciting dose predicted to provoke an allergic reaction in 10% of individuals (ED 10 ), on the basis of dose distribution curves (see Table E4 and Fig E4 in this article's Online Repository at www.jacionline.org). We found ED 10 to be 0.7 mg and 23.8 mg of cod protein for subjective and objective symptoms, respectively, in line with previously published data. 8 Low number of participants with objective reactions to salmon and mackerel restricted us from producing reliable dose distribution curves but a comparison of lowest observed adverse effect levels (LOAELs) for objective symptoms to cod, salmon, and mackerel (see Fig E5, A-C, in this article's Online Repository at www.jacionline.org) shows more participants with low LOAELs for cod compared with salmon and mackerel. This is the first DBPCFC trial comparing clinical and sIgE cross-reactivity to fish-allergen molecules with different fish species. More than half of all participants had objective tolerance, and around one-third had subjective tolerance to at least 1 fish species. By combining sIgE against conventional fish-allergen extracts and fish-allergen molecules, we could predict the outcome of challenge in most patients. Cod allergy was most prevalent and cod elicited more serious symptoms and had lower ED 10 /LOAELs, compared with salmon and mackerel. This may be due to local dietary traditions with high consumption of cod and cod being the primary sensitizer. Although unproven, differences in parvalbumin stability between species may theoretically play a role. The poor ability of fish-allergen extracts and parvalbumins to identify tolerance to specific fish species may be due to sIgE-cross-reactive parvalbumins. 4, 9 More sensitization to cod enolase/aldolase, compared with salmon and mackerel enolase/aldolase, may be due to less interspecies IgE crossreactivity between enolases/aldolases and cod being the primary cause of sensitization.
Although allergen levels may vary in different allergen extract batches, 9 patients with an obvious history of self-reported fish allergy and sIgE of more than 8.2 kU A /L to cod extract or more than 5 kU A /L to salmon extract may be advised to avoid all fish species. Mackerel extract is less reliable because median IgE to extract is lower than to parvalbumin (Table E3 ). Sensitization to enolase/aldolase most likely reflects true fish allergy, whereas nonsensitized patients may be allergic and must undergo a challenge. However, based on our results, an OFC protocol could be prepared for low-risk patients to test new fish species in small amounts without the need of a full DBPCFC. Our results indicate that sIgE to enolase/aldolase may have a role in diagnosing fish allergy when it comes to cod, salmon, and mackerel.
A limitation of this study is the low number of participants, attenuating the power to detect differences between groups. Second, children of lower age had higher dropout rates due to poor palatability of the test food, but none dropped out because of allergic reactions. We believe that the data represent good estimates of cross-reactivity and severity in the fish-allergic population but results may not be applicable to other regions. The main strength is the randomized, placebo-controlled design using standardized test food, followed by OFC. The basophil activation test will be included in a follow-up to further elaborate on the diagnostic differentiation between sensitization and true allergy.
In summary, more than half of the participants had no objective symptoms, and around one-third, no subjective symptoms to at least 1 fish species. Doses provoking allergic reactions are lower for cod than for salmon and mackerel. Patients with partial tolerance should be identified to avoid unnecessary food restrictions. A combination of clinical history and sIgE to fishallergen extracts and molecules can significantly reduce the number of food challenges needed for specific diagnosis of fish allergy.
We are thankful to all the participants and their parents who spent up to 7 days to participate, many of them eating test food they did not like and gave them allergic reactions. We greatly appreciate the professional work of the staff at the Department of Research, University Hospital of North Norway for performing all the DBPCFs and OFCs. Without their enthusiastic contribution, this study would not have been possible. A, Sensitization to fish extracts and molecules in participants with objective (n 5 32), only subjective (n 5 1), and no symptoms (n 5 2) to cod during DBPCFC/OFC. *DBPCFC/OFC 5 Food-challenge cod. Light blue bar, first group of bars: Number of participants with objective symptoms during cod challenge. Light blue bar, second group of bars: Number of participants with only subjective symptoms during cod challenge. Light blue bar, third group of bars: Number of participants with no symptoms during cod challenge. All other bars are number of participants sensitized (sIgE > 0.1 kU A /L) to cod using 4 different fish-allergen assays. B, Sensitization to fish extracts and molecules in participants with objective (n 5 23), only subjective (n 5 5), and no symptoms (n 5 7) to salmon during DBPCFC/OFC. *DBPCFC/OFC 5 Food-challenge salmon. Light blue bar, first group of bars: Number of participants with objective symptoms during salmon challenge. Light blue bar, second group of bars: Number of participants with only subjective symptoms during salmon challenge. Light blue bar, third group of bars: Number of participants with no symptoms during salmon challenge. All other bars are number of participants sensitized (sIgE > 0.1 kU A /L) to salmon using 4 different fish-allergen assays. C, Sensitization to fish extracts and molecules in participants with objective (n 5 19), only subjective (n 5 9), and no symptoms (n 5 7) to mackerel during DBPCFC/OFC. *DBPCFC/OFC 5 Food-challenge mackerel. Light blue bar, first group of bars: Number of participants with objective symptoms during mackerel challenge. Light blue bar, second group of bars: Number of participants with only subjective symptoms during mackerel challenge. Light blue bar, third group of bars: Number of participants with no symptoms during mackerel challenge. All other bars are number of participants sensitized (sIgE > 0.1 kU A /L) to mackerel using 4 different fish-allergen assays. Figure E2a , Online Repository. Number of participants (N=35) with objective symptoms to cod, salmon and mackerel during DBPCFC/OFC.
Mouth: swellings/blisters in the mouth or on the lips. Skin: Erythema, urticaria or angioedema of the skin. Nose: Sneeze or itchy, runny, blocked nose. Eye:
Itchy, red or watery eyes. No participants had stridor, wheeze, tachycardia, arrhythmia, syncope, seizures or incontinence. 
